To further evaluate the role of serum CXCL13 in the prediction of recurrence-free survival of HBV-related HCC patients, survival analysis were performed especially in those with a lower AFP level (≤200 ng/ml). This evidence concerns the gene AFP and hepatocellular carcinoma.